Review decision: June 2015
We checked this guideline and decided that it should be updated at this time. For details, see the update decision and the process for deciding if an update is needed. Details of the update will be available on the guidelines in development webpage in due course. This guideline will be checked again for update at its scheduled time point according to the methods described here.
Next review date: September 2016
In July 2016, recommendations 220.127.116.11–18.104.22.168 were replaced and are adapted from ezetimibe for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia (NICE technology appraisal guidance 385). TA385 has replaced TA132, the original source for these recommendations.
The advice in the NICE guideline covers the care and treatment of adults and children/young people with familial hypercholesterolaemia (a specific type of inherited high cholesterol that runs in the family).
It does not cover other forms of hypercholesterolaemia that are not genetic (inherited) or that are due to other genetic conditions.
This guideline was previously called identification and management of familial hypercholesterolaemia.
Responsibility for undertaking a review of this guidance at the designated review date has passed to the National Clinical Guidelines Centre for Acute and Chronic Conditions (NCGCACC). The National Collaborating Centre for Primary Care is no longer active.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.